Journal of Clinical Oncology, Vol 1, 146-153, Copyright © 1983 by American Society of Clinical Oncology

ARTICLES

A dose and time response analysis of the treatment of Hodgkin's disease with MOPP chemotherapy

P Carde, FR MacKintosh and SA Rosenberg

A dose-response analysis of the results of MOPP chemotherapy in 132 patients with Hodgkin's disease was carried out. Complex statistical methods were utilized including 40 different dose-time variables and multivariate logistic analyses of 21 clinical variables, both simply and in stepwise regression. These covariates were not independent, and in stepwise regression analysis only B-symptoms and the mean three- cycle rate of drug delivery significantly influenced complete remission attainment. Two parameters, bone marrow involvement (negative) and lung involvement (positive), significantly influenced the duration of complete remission. Survival was influenced adversely by pleural involvement (effusion), advanced age, and B-symptoms. Analyses indicate that the dose of all three drugs (mustard, vincristine, and procarbazine), and the rate of drug delivery during the first three cycles are important in achieving maximal complete response rates, especially for patients with B-symptoms.

This article has been cited by other articles:

				E. Boleti and G. Mead ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors Ann. Onc., February 1, 2007; 18(2): 376 - 380. [Abstract] [Full Text] [PDF]

				M. Federico, M. Bellei, P. Brice, M. Brugiatelli, A. Nagler, C. Gisselbrecht, L. Moretti, P. Colombat, S. Luminari, F. Fabbiano, et al. High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin's Lymphoma Responding to Front-Line Therapy J. Clin. Oncol., June 15, 2003; 21(12): 2320 - 2325. [Abstract] [Full Text] [PDF]

				H. Tesch, V. Diehl, B. Lathan, D. Hasenclever, M. Sieber, U. Ruffer, A. Engert, J. Franklin, M. Pfreundschuh, K.P. Schalk, et al. Moderate Dose Escalation for Advanced Stage Hodgkin's Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin's Lymphoma Study Group Blood, December 15, 1998; 92(12): 4560 - 4567. [Abstract] [Full Text] [PDF]

				V. T. DeVita and S. M. Hubbard Hodgkin's Disease N. Engl. J. Med., February 25, 1993; 328(8): 560 - 565. [Full Text]

				C. F. Stewart Pharmacodynamics and Cancer: Practical Aspects of Dose Intensity for Pharmacists Journal of Pharmacy Practice, January 1, 1991; 4(1): 11 - 19. [Abstract] [PDF]